deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT01283581

A Study to Assess Objective Endpoint Measurements of Response in Bacterial Skin Infections

A Phase 2 Exploratory Study of Objective Endpoints in Subjects With Acute Bacterial Skin and Skin Structure Infections Treated With Delafloxacin, Vancomycin, or Linezolid

Sponsor: Melinta Therapeutics, Inc.

Updated 8 times since 2017 Last updated: Sep 25, 2019 Started: Jan 31, 2011 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Skin and Subcutaneous Tissue Bacterial Infections, this trial is completed. The trial is conducted by Melinta Therapeutics, Inc. and has accumulated 8 data snapshots since 2011. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Nov 2019 · 17 months · monthly snapshotCompleted~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE2

Show 3 earlier versions
  1. Jun 2018 — Nov 2019 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Melinta Therapeutics, Inc.
Data source: Melinta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .